Aquestive Therapeutics, Inc. (AQST) Cash Flow Statement
Aquestive Therapeutics, Inc. (AQST) generated -$45.4M of operating cash flow over the twelve months to 2026-06-30, spent $584000 on capital expenditure and had free cash flow of -$45.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AQSTAquestive Therapeutics, Inc.Follow AQST — free
—
Price chart with a free account
- Market cap
- 502.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -13.0 | -60.2 | -45.5 | -33.0 | -9.8 | -6.4 | -35.8 | -52.4 | -45.4 | |
| Capital expenditure | 1.8 | 0.7 | 0.5 | 0.9 | 1.0 | 1.0 | 0.2 | 0.6 | -0.6 | |
| Free cash flow | -14.8 | -60.9 | -46.0 | -33.9 | -10.8 | -7.4 | -35.9 | -53.0 | -45.9 | |
| Stock-based compensation | 29.9 | 7.1 | 6.6 | 6.8 | 4.4 | 2.7 | 7.1 | 7.6 | — |
USD millions · SEC XBRL
Aquestive Therapeutics, Inc. — questions
- What is Aquestive Therapeutics, Inc.'s operating cash flow?
- -$45.4M over the twelve months to 2026-06-30.
- How much does Aquestive Therapeutics, Inc. spend on capital expenditure?
- $584000 over the twelve months to 2026-06-30.
- What is Aquestive Therapeutics, Inc.'s free cash flow?
- -$45.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Aquestive Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.